Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder

Human Psychopharmacology

Volumn 22, Issue 3, 2007, Pages 129-133

  Mbaya, Patrick ^a   Alam, Faouzi ^a   Ashim, Sindhu ^a   Bennett, David ^b  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

Cardiovascular; Major depressive disorder; Venlafaxine XL

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; BENZODIAZEPINE; BUSPIRONE; DIGOXIN; GABAPENTIN; HYPERTENSIVE AGENT; LAMOTRIGINE; LITHIUM; NEUROLEPTIC AGENT; OPIATE; PREDNISOLONE; THYROXINE; VENLAFAXINE; ZOPICLONE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR EFFECT; CLINICAL ARTICLE; DRUG MEGADOSE; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; HEART RATE; HUMAN; HYPERTENSION; MAJOR DEPRESSION; MALE; PR INTERVAL; PRIORITY JOURNAL; PSYCHOSIS; QRS COMPLEX; QT INTERVAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BLOOD PRESSURE; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; STATISTICS;

EID: 34248376975     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.834     Document Type: Article

References (20)

1. Botstein P. 1993. Is QT interval prolongation harmful? A regulatory perspective. Am J Cardiol 72(6): 50B-52B.
2. Chobanian AV, Bakris GL, Black HR, et al. 2003. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289: 2560-2572.
3. Committee on Safety of Medicines (CSM). 2004.
4. Edwards JG, Dinan TG, Waller DG, et al. 1996. Double-blind comparative study of the antidepressant, unwanted and cardiac effects of minaprine and amitriptyline. Br J Clin Pharmacol 42: 491-498.
5. Glassman AH. 1998. Cardiovascular effects of antidepressant drugs: updated. J Clin Psychiatry 59(Suppl. 15): 13-18.
6. Haddad PM, Anderson IM. 2002. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 62: 1649-1671.
7. Harrigan RA, Brady WJ. 1999. ECG abnormalities in tricyclic antidepressant ingestion. Am J Emerg Med 17: 387-393.
8. Harvey AT, Rudolph RL, Preskorn SH. 2000. Evidence of dual mechanism of action of venlafaxine. Arch Gen Psychiatry 57: 503-509.
9. Hawley C. 2005. How prescriptive is the NICE guideline on depression? Prog Neurol Psychiatry 6: 8-10.
10. Khawaja IS, Feinstein RE. 2003. Cardiovascular effects of selective serotonin reuptake inhibitors and other novel antidepressants. Heart Dis 5: 153-160.
11. Malik M, Camm AJ. 2001. Evaluation of drug induced QT interval prolongation. Implications for drug approval and labelling. Drug Saf 24(5): 323-351.
12. Muthe EA, Haskins JT, Moyer JA, et al. 1986. Antidepressant biochemical profile of novel bicyclic compound WY-45, 030,an ethyl cyclo hexanol derivative. Biochem Pharmacol 35(24): 4493-4497.
13. National Institute of Clinical Excellence (NICE) Guide 23. 2004 December.
14. Physician's Desk Reference. Ed. 55. Medical Economics Company: Montvale, NJ, 2001.
15. Stahl SM. 2000. Neuroscientific Basis And Practical Applications. Essential Psychopharmacology, 2nd edn, Cambridge University Press: Cambridge.
16. Taylor DM. 2003. Antipsychotics and QT prolongation. Acta Psychiatr Scand 107: 85-95.
17. Thase M. 1998. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3,744 depressed patients. J Clin Psychiatry 59(10): 502-509.
18. Thase ME, Tran PV, Wiltse C, et al. 2005. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol 25(2): 132-140.
19. Witchel HJ, Hancox JC, Nutt DJ. 2003. Psychotropic drugs, cardiac arrhythmia, and sudden death. J Clin Psychopharmacol 23: 58-77.
20. Wyeth Report. 2004. Summary of Clinical Trials.